EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Senolytic Treatment Reduces Acute and Chronic Lung Inflammation in an Aged Mouse Model of Influenza

Lou Delval, Marybeth Creskey, Clara Valentin, Clément Bordas, Stefano Raviola iD, Larissa Lipskaia iD, Séverine Heumel iD, Lucie Deruyter, Valentin Sencio iD, Isabelle Wolowczuk iD, David Bernard iD, Serge Adnot iD und 3 weitere

Aging Cell · 2026-04 · 25 (4)

DOI: 10.1111/acel.70480 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Aging Cell, online erschienen am 08.04.2026. Verfasst von Lou Delval und 14 weiteren Autor:innen. Beteiligte Einrichtung: CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, Univ. Lille, Lille, France. Hauptthemen laut MEDLINE: Senotherapeutics, Pneumonia, Sulfonamides, Orthomyxoviridae Infections. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agence Nationale de la Recherche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Influenza A virus continues to pose a significant global health burden, with older individuals experiencing disproportionate morbidity and mortality. Although aging is associated with the accumulation of senescent cells, the extent to which cellular senescence contributes to influenza severity remains poorly understood. The aim of this study was to evaluate the therapeutic potential of the senolytic drug ABT‐263, a B cell lymphoma‐2 inhibitor, in mitigating both acute and chronic damage in an aged mouse model of influenza. Early administration of ABT‐263, beginning one day prior to infection, did not prevent body weight loss, reduce pulmonary viral load, or improve clinical scores in aged mice. However, ABT‐263 treatment significantly reduced lung inflammation in aged mice, coinciding with changes in the expression of senescence‐associated markers. ABT‐263 also reduced intestinal inflammation and mitigated virus‐induced gut dysbiosis, a known contributor to disease severity and secondary outcomes. Although the treatment lowered antigen‐specific CD8 + T cell responses, it did not affect influenza‐specific antibody production nor pulmonary defense against reinfection. Notably, ABT‐263 reduced long‐term pulmonary sequelae including edema, type II hyperplasia, emphysema and epithelial damage. Overall, ABT‐263 therapy partially mitigates influenza severity in aged mice, primarily through dampening acute and chronic inflammation. Most of these effects were age‐dependent, suggesting a role for pre‐existing senescent cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SenotherapeuticsPneumoniaSulfonamidesOrthomyxoviridae InfectionsAniline CompoundsAgingInfluenza, HumanAnimalsMiceDisease Models, AnimalChronic DiseaseAcute DiseaseCellular SenescenceMice, Inbred C57BLInfluenza A virusFemale

Stichwörter der Autor:innen

acute responseadvanced agecellular senescencechronic damagedysbiosisinflammationinfluenzasenolysis

Substanzen

navitoclaxSenotherapeuticsSulfonamidesAniline Compounds

Autor:innen und Institutionen

  • CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, Univ. Lille, Lille, France.
  • Regulatory Research Division, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada Ottawa, Canada University, Ottawa, Canada.
  • INSERM U955, Institut Mondor de Recherche Biomédicale (IMRB), FHU SENEC, University Paris-Est Créteil, Créteil, France.
  • Département de Physiologie-Explorations Fonctionnelles and FHU SENEC, Hôpital Henri Mondor, AP-HP, Créteil, France.
  • Equipe Labellisée la Ligue Contre le Cancer, Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France.
  • School of Pharmaceutical Sciences, Faculty of Medicine, University of Ottawa, Ottawa, Canada.

ORCID-Profile: Stefano Raviola, Larissa Lipskaia, Séverine Heumel, Valentin Sencio, Isabelle Wolowczuk, David Bernard, Serge Adnot, François Trottein

Förderung

  • Agence Nationale de la Recherche

Zitieren

APA

Delval, L., Creskey, M., Valentin, C., Bordas, C., Raviola, S., Lipskaia, L., Heumel, S., Deruyter, L., Sencio, V., Wolowczuk, I., Bernard, D., Adnot, S., Gosset, P., Zhang, X., & Trottein, F. (2026). Senolytic Treatment Reduces Acute and Chronic Lung Inflammation in an Aged Mouse Model of Influenza. Aging Cell, 25(4). https://doi.org/10.1111/acel.70480

Vancouver

Delval L, Creskey M, Valentin C, Bordas C, Raviola S, Lipskaia L, et al. Senolytic Treatment Reduces Acute and Chronic Lung Inflammation in an Aged Mouse Model of Influenza. Aging Cell. 2026;25(4). doi:10.1111/acel.70480

BibTeX
@article{Delval2026,
  author = {Delval, Lou and Creskey, Marybeth and Valentin, Clara and Bordas, Clément and Raviola, Stefano and Lipskaia, Larissa and Heumel, Séverine and Deruyter, Lucie and Sencio, Valentin and Wolowczuk, Isabelle and Bernard, David and Adnot, Serge and Gosset, Philippe and Zhang, Xu and Trottein, François},
  title = {Senolytic Treatment Reduces Acute and Chronic Lung Inflammation in an Aged Mouse Model of Influenza},
  journal = {Aging Cell},
  year = {2026},
  volume = {25},
  number = {4},
  doi = {10.1111/acel.70480}
}
Kostenlos starten →